Literature DB >> 25897791

Disubstituted Bis-THF Moieties as New P2 Ligands in Nonpeptidal HIV-1 Protease Inhibitors (II).

Konrad Hohlfeld1, Jörg Kurt Wegner2, Bart Kesteleyn2, Bruno Linclau1, Johan Unge3.   

Abstract

A series of darunavir analogues featuring a substituted bis-THF ring as P2 ligand have been synthesized and evaluated. Very high affinity protease inhibitors (PIs) with an interesting activity on wild-type HIV and a panel of multi-PI resistant HIV-1 mutants containing clinically observed, primary mutations were identified using a cell-based assay. Crystal structure analysis was conducted on a number of PI analogues in complex with HIV-1 protease.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25897791     DOI: 10.1021/acs.jmedchem.5b00358

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

Review 1.  Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.

Authors:  Arun K Ghosh; Heather L Osswald; Gary Prato
Journal:  J Med Chem       Date:  2016-01-22       Impact factor: 7.446

2.  Novel HIV-1 Protease Inhibitors with Morpholine as the P2 Ligand to Enhance Activity against DRV-Resistant Variants.

Authors:  Mei Zhu; Yue Dou; Ling Ma; Biao Dong; Fan Zhang; Guoning Zhang; Juxian Wang; Jinming Zhou; Shan Cen; Yucheng Wang
Journal:  ACS Med Chem Lett       Date:  2020-03-31       Impact factor: 4.345

3.  Design, synthesis, biological evaluation and X-ray structural studies of HIV-1 protease inhibitors containing substituted fused-tetrahydropyranyl tetrahydrofuran as P2-ligands.

Authors:  Arun K Ghosh; Cuthbert D Martyr; Luke A Kassekert; Prasanth R Nyalapatla; Melinda Steffey; Johnson Agniswamy; Yuan-Fang Wang; Irene T Weber; Masayuki Amano; Hiroaki Mitsuya
Journal:  Org Biomol Chem       Date:  2015-10-14       Impact factor: 3.876

4.  An insight to the molecular interactions of the FDA approved HIV PR drugs against L38L↑N↑L PR mutant.

Authors:  Zainab K Sanusi; Thavendran Govender; Glenn E M Maguire; Sibusiso B Maseko; Johnson Lin; Hendrik G Kruger; Bahareh Honarparvar
Journal:  J Comput Aided Mol Des       Date:  2018-02-03       Impact factor: 3.686

5.  Design, Synthesis and X-Ray Structural Studies of Potent HIV-1 Protease Inhibitors Containing C-4 Substituted Tricyclic Hexahydro-Furofuran Derivatives as P2 Ligands.

Authors:  Arun K Ghosh; Satish Kovela; Ashish Sharma; Dana Shahabi; Ajay K Ghosh; Denver R Hopkins; Monika Yadav; Megan E Johnson; Johnson Agniswamy; Yuan-Fang Wang; Shin-Ichiro Hattori; Nobuyo Higashi-Kuwata; Manabu Aoki; Masayuki Amano; Irene T Weber; Hiroaki Mitsuya
Journal:  ChemMedChem       Date:  2022-03-04       Impact factor: 3.540

6.  Design and Synthesis of Highly Potent HIV-1 Protease Inhibitors Containing Tricyclic Fused Ring Systems as Novel P2 Ligands: Structure-Activity Studies, Biological and X-ray Structural Analysis.

Authors:  Arun K Ghosh; Prasanth R Nyalapatla; Satish Kovela; Kalapala Venkateswara Rao; Margherita Brindisi; Heather L Osswald; Masayuki Amano; Manabu Aoki; Johnson Agniswamy; Yuan-Fang Wang; Irene T Weber; Hiroaki Mitsuya
Journal:  J Med Chem       Date:  2018-05-15       Impact factor: 7.446

7.  Design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors incorporating aminothiochromane and aminotetrahydronaphthalene carboxamide derivatives as the P2 ligands.

Authors:  Arun K Ghosh; Ravindra D Jadhav; Hannah Simpson; Satish Kovela; Heather Osswald; Johnson Agniswamy; Yuan-Fang Wang; Shin-Ichiro Hattori; Irene T Weber; Hiroaki Mitsuya
Journal:  Eur J Med Chem       Date:  2018-09-18       Impact factor: 6.514

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.